Scribe Therapeutics' STX-1150: Silencing PCSK9 Epigenetically Without Editing Your DNA
BiohackingScribe Therapeutics has received Phase 1 clearance from Australia’s Therapeutic Goods Administration for STX-1150, a single-dose epigenetic treatment that reduced LDL cholesterol by more than 50% in primate studies and maintained that reduction for approximately 18 months — without modifying the underlying DNA sequence.
The Mechanism: Epigenetic Silencing vs. Genetic Editing
The distinction matters for how this therapy sits relative to existing cholesterol interventions. Statins require ongoing daily dosing and work by inhibiting HMG-CoA reductase. PCSK9 inhibitor biologics (evolocumab, alirocumab) also require regular injection. Gene therapies that target PCSK9 permanently alter the DNA sequence — a one-time intervention with irreversible consequences.
STX-1150 uses Scribe’s ELXR platform to silence the PCSK9 gene epigenetically: the gene remains intact and unaltered, but its expression is suppressed through modifications to the regulatory layer above the DNA. This is a reversible mechanism in principle — the epigenetic marks can be reset — which positions it differently from permanent gene editing on the safety and reversibility spectrum. The approximately 18-month duration seen in Scribe’s primate data would represent a fundamentally different treatment cadence than any current standard-of-care option.
The Phase 1 Trial Design
The TGA clearance covers an open-label single ascending dose trial in Australia and New Zealand, enrolling up to 64 participants. The single ascending dose design is standard Phase 1 methodology: start at a dose below the efficacious range, escalate systematically, and characterize the safety and pharmacokinetic profile before moving to efficacy-focused phases. The primate data showing >50% LDL reduction below 1.0 mg/kg provides the human dose estimation anchor — a low effective dose in primates is favorable for translating to human therapeutic windows.
The longevity medicine framework that Peter Attia has outlined places cardiovascular risk reduction — specifically LDL and Lp(a) management — among the highest-leverage interventions available for extending healthspan. PCSK9 inhibition sits at the center of that framework; a durable, single-dose epigenetic approach would address the primary practical friction point of existing PCSK9 therapies, which is ongoing injection burden.
The So What
STX-1150 is early-stage — Phase 1 trials establish safety and tolerability, not efficacy, and the distance from primate data to human approval is substantial. But the mechanism is genuinely novel: reversible epigenetic silencing occupying the space between ongoing pharmaceutical dosing and permanent gene editing. For people already engaged in aggressive cardiovascular risk management, this is a trial worth tracking rather than acting on. The 18-month durability claim in primates is the number that will be scrutinized most closely in human data. Consult a qualified healthcare provider before making any changes to cholesterol management or treatment protocols based on early-phase trial data.
Photo by Artem Podrez on Pexels
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →